Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
Gilead (Nasdaq: GILD) subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Florida, USA-based Summit Therapeutics has managed to beat the leading checkpoint blocker, Keytruda (pembrolizumab), in a head-to-head comparison. 4 June 2024
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO- 4 June 2024
The market for branded multiple myeloma drugs is projected to grow to $33 billion by 2030, up from $23.5 billion in 2023, according to Bloomberg Intelligence (B 4 June 2024
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical 3 June 2024
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strengt 3 June 2024
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (A 3 June 2024